N/A
Manufactured by Alcon Laboratories, Inc.
1,545 FDA adverse event reports analyzed
Last updated: 2026-04-15
PROPARACAINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Alcon Laboratories, Inc.. The most commonly reported adverse reactions for PROPARACAINE HYDROCHLORIDE include OFF LABEL USE, CONJUNCTIVAL HYPERAEMIA, EYE PAIN, DRUG ABUSE, CORNEAL OEDEMA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PROPARACAINE HYDROCHLORIDE.
Out of 505 classified reports for PROPARACAINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,545 FDA FAERS reports that mention PROPARACAINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, CONJUNCTIVAL HYPERAEMIA, EYE PAIN, DRUG ABUSE, CORNEAL OEDEMA, HYPOPYON. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Alcon Laboratories, Inc. in connection with PROPARACAINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.